Neonatal Screening for Phenylalanine

Neonatal Screening for Phenylalanine is a newborn blood-spot test used to identify babies who may have an abnormally high concentration of phenylalanine. Phenylalanine is an essential amino acid obtained from protein-containing foods. It is required for normal growth, but excessive accumulation can be harmful to the developing brain.

The principal condition detected through this screening is phenylketonuria, commonly abbreviated as PKU. PKU is an inherited metabolic disorder in which the body cannot process phenylalanine effectively. In most cases, this occurs because the enzyme phenylalanine hydroxylase has reduced or absent activity. This enzyme normally converts phenylalanine into another amino acid called tyrosine.

Babies with PKU usually appear healthy at birth. Without screening, the condition may remain unrecognised until high phenylalanine levels have affected brain development. Early identification allows confirmatory testing and specialist treatment to begin before preventable neurological complications develop.

The phenylalanine newborn test is a screening investigation rather than a definitive diagnostic test. An out-of-range result does not independently confirm PKU. It indicates that the baby requires prompt clinical evaluation, repeat or quantitative phenylalanine measurement and additional metabolic investigations.

Benefits of Phenylalanine Newborn Screening

• Identifies newborns with elevated blood phenylalanine before symptoms appear.
• Supports early detection of phenylketonuria and related metabolic conditions.
• Uses a small dried blood spot collected through a heel prick.
• Can be included in a broader newborn metabolic screening panel.
• Enables prompt confirmatory plasma amino acid testing.
• Supports early referral to a paediatric metabolic specialist.
• May allow treatment to begin before irreversible neurological injury develops.
• Helps distinguish babies who require further testing from those with an in-range screen.
• Provides important information for families with a history of PKU.
• Supports long-term developmental health through timely diagnosis and management.

Understanding Phenylketonuria

Phenylketonuria is most commonly caused by disease-causing variants in the PAH gene. The PAH gene provides instructions for producing phenylalanine hydroxylase. When this enzyme does not function adequately, phenylalanine and related metabolites accumulate in the blood and tissues.

PKU usually follows an autosomal recessive inheritance pattern. An affected baby generally inherits one altered gene copy from each biological parent. Parents with one altered copy are typically healthy carriers and may not know that they carry the condition.

When both parents are carriers of disease-causing variants in the same PAH gene, each pregnancy generally has a 25% probability of an affected child, a 50% probability of a carrier child and a 25% probability of a child who inherited neither familial variant. Genetic counselling can explain the risk for an individual family.

PKU varies in severity. Classical PKU generally causes marked elevation of phenylalanine and requires carefully supervised treatment. Milder PAH deficiency may result in less pronounced hyperphenylalaninaemia. Rare disorders involving tetrahydrobiopterin, a cofactor required for phenylalanine metabolism, can also cause increased phenylalanine and require a different treatment approach.

Untreated or inadequately treated PKU can affect intellectual development, behaviour, attention, movement and neurological function. Early treatment greatly improves outcomes, which is why newborn screening is important even when the baby appears completely healthy.

What Does the Screening Test Measure?

The test measures phenylalanine in a dried blood spot collected from the newborn's heel. Many modern screening laboratories use tandem mass spectrometry. Some screening methods evaluate phenylalanine concentration together with the phenylalanine-to-tyrosine ratio to improve detection.

The laboratory compares the result with method-specific and age-appropriate screening thresholds. Exact cut-offs vary according to the laboratory, analytical method, specimen timing and newborn screening programme. A result should always be interpreted using the reference information supplied by the performing laboratory.

An elevated screening value is described as screen positive, out of range or requiring follow-up. It does not specify the exact cause. Classical PKU, milder PAH deficiency, tetrahydrobiopterin-related disorders, liver dysfunction, prematurity, illness, nutritional factors and specimen-related issues may contribute to an abnormal result.

Clinical Indications and Applications

Routine Newborn Screening: Phenylalanine testing is primarily performed as part of early newborn metabolic screening. Collection timing should follow the recommendations of the baby's paediatrician and the applicable screening programme.

Family History of PKU: Babies with an affected sibling or known parental carrier status require targeted evaluation. A routine newborn screen may not be sufficient for a high-risk baby. The specialist may recommend immediate quantitative amino acid testing and molecular analysis.

Out-of-Range Initial Result: Babies with an elevated or borderline result require prompt follow-up. Depending on the concentration and clinical context, the doctor may request another dried blood spot, quantitative plasma amino acids or additional metabolic tests.

Unsuitable Initial Specimen: An insufficient, contaminated, wet, layered or improperly collected blood spot may not produce a reliable result. Recollection should be performed promptly.

Premature or Critically Ill Newborns: Prematurity, total parenteral nutrition, blood transfusion, liver dysfunction and serious illness can influence newborn screening results. Repeat specimens may be required according to the clinical protocol.

Why Doctors Recommend This Test

PKU may not produce visible signs during the first days of life, even though phenylalanine is beginning to accumulate. Waiting for developmental or neurological symptoms would delay treatment beyond the ideal period. Screening provides an opportunity to identify risk before preventable injury occurs.

When PKU is confirmed, treatment commonly includes a medically supervised diet that restricts phenylalanine while supplying adequate protein, energy, vitamins and minerals for growth. Special medical formulas may be prescribed. Some patients may be eligible for additional treatments after specialist assessment.

Parents must not independently remove protein, breast milk or formula from a newborn's diet. Phenylalanine is an essential amino acid and cannot be eliminated completely. Treatment requires precise nutritional management by a paediatric metabolic physician and qualified metabolic dietitian.

Preparation Before the Test

No fasting is required for neonatal phenylalanine screening. The baby should generally continue normal breastfeeding or formula feeding unless a paediatric metabolic specialist provides different instructions. Feeding information may help the laboratory interpret the result.

The collection team should document the baby's date and time of birth, gestational age, birth weight, feeding method, specimen collection time, transfusion history and use of total parenteral nutrition. The laboratory should also be informed if the baby is premature, critically ill or receiving intensive care.

Collection timing can influence the result. Many programmes collect newborn blood spots after the baby has begun protein feeding and within the first few days after birth. Babies discharged very early or tested before the recommended interval may require a repeat specimen.

If another child in the family has PKU or both parents are known carriers, inform the obstetrician, neonatologist and paediatric metabolic specialist before delivery whenever possible. High-risk babies may require immediate diagnostic evaluation rather than waiting only for routine screening.

Dried Blood Spot Collection Procedure

A trained healthcare professional warms and cleans the baby's heel before making a small puncture with a sterile newborn lancet. Drops of blood are allowed to form naturally and are applied directly to the marked circles on an approved filter-paper collection card.

Each marked circle should be filled adequately so that blood saturates the paper and is visible from the reverse side. Excessive squeezing of the heel, touching the filter paper, repeatedly layering blood drops or applying blood incorrectly can produce an unsuitable specimen.

After collection, gentle pressure is applied to the heel until bleeding stops. The card is dried horizontally in a clean area away from direct sunlight, heat, moisture and chemical fumes. The dried card is then packaged and transported according to laboratory requirements.

The heel-prick procedure may cause brief discomfort. Minor bruising or tenderness can occur, but significant complications are uncommon. An unsuitable blood spot may need to be recollected to ensure reliable screening.

Laboratory Analysis and Reporting

The laboratory extracts amino acids from the dried blood spot and measures phenylalanine using tandem mass spectrometry or another validated method. Depending on the screening process, the laboratory may also assess tyrosine and calculate the phenylalanine-to-tyrosine ratio.

The report may state screen negative, screen positive, out of range, borderline or repeat specimen required. A numerical phenylalanine value may also be provided. The dried blood spot screening value should not be interpreted as equivalent to a diagnostic plasma phenylalanine concentration without specialist review.

An elevated result generally requires quantitative plasma amino acid analysis. The doctor may also request urine testing, pterin analysis, dihydropteridine reductase assessment or molecular genetic testing to distinguish PAH-related PKU from tetrahydrobiopterin disorders and other causes of hyperphenylalaninaemia.

Treatment decisions should be based on confirmatory results and specialist assessment. A symptomatic or high-risk baby should receive urgent medical evaluation without waiting for all screening or genetic reports to become available.

Normal Reporting Time

The report for Neonatal Screening for Phenylalanine is generally available within 2 to 3 working days after the laboratory receives an acceptable dried blood spot. Actual reporting time may vary with specimen transport, laboratory workflow, testing method and the need for repeat analysis.

Out-of-range results may be communicated urgently according to laboratory policy. Confirmatory plasma amino acid analysis, specialised biochemical testing and genetic testing require separate samples and additional reporting time.

Who Should Consider This Test?

• Newborn babies undergoing routine metabolic screening.
• Babies with a family history of phenylketonuria.
• Newborns whose parents are known PAH variant carriers.
• Babies with an affected sibling.
• Newborns requiring repeat testing after a borderline result.
• Babies whose initial dried blood spot was unsuitable.
• Premature babies following the recommended repeat-screening protocol.
• Critically ill newborns advised to undergo metabolic screening.
• Babies receiving parenteral nutrition or who have received a transfusion.
• Any newborn specifically referred by a neonatologist or metabolic specialist.

Understanding the Screening Results

Screen Negative: A result within the screening threshold means that increased phenylalanine was not identified in that specimen. It reduces the likelihood of classical PKU but does not exclude every mild or variant disorder.

Screen Positive or Out of Range: An elevated phenylalanine result indicates that urgent follow-up is required. It does not independently confirm PKU. Quantitative plasma amino acids and specialist evaluation are necessary.

Borderline Result: A value close to the screening threshold may require a repeat dried blood spot or direct diagnostic testing. The appropriate action depends on the baby's age, result, feeding status and clinical condition.

Unsatisfactory Specimen: An insufficient or poor-quality specimen cannot provide reliable screening. Recollection should occur promptly using the laboratory's collection instructions.

If confirmatory testing shows persistently increased phenylalanine, the specialist will determine whether the baby has classical PKU, milder PAH deficiency, a tetrahydrobiopterin-related disorder or another cause of hyperphenylalaninaemia.

Clinical Limitations

Neonatal phenylalanine testing is a screening procedure and cannot independently establish a diagnosis, predict disease severity or determine the complete treatment plan. False-positive and false-negative results are possible.

Specimen collection too early, insufficient protein exposure, prematurity, parenteral nutrition, transfusion, liver disease, serious illness, delayed transport and an unsuitable blood spot can affect screening accuracy. Laboratory methods and thresholds also differ.

Mild forms of PAH deficiency may not produce a clearly abnormal result during the newborn period. A normal screen should not override a strong family history or compatible clinical findings. High-risk babies may require diagnostic testing even when the screening result is in range.

The result does not distinguish all causes of increased phenylalanine. Additional biochemical and genetic investigations are required to determine the underlying disorder and select the appropriate treatment.

Important Safety Information

An out-of-range phenylalanine screen requires prompt paediatric follow-up, but parents should not panic because screening results can be abnormal for reasons other than PKU. The result must be confirmed using appropriate diagnostic investigations.

Do not stop breastfeeding, formula or protein intake without instructions from a paediatric metabolic specialist. Unsupervised dietary restriction can cause inadequate nutrition and harm the baby's growth. Confirmed PKU requires an individual treatment plan, specialised nutrition, regular phenylalanine monitoring and long-term clinical follow-up.